We regret to inform you that Bristol Myers Squibb (BMS) has made the difficult decision to discontinue the production and supply of COUMADIN (warfarin sodium) in Canada, the United States, Latin America, and Saudi Arabia, due to an unexpected manufacturing issue that could not be resolved expeditiously, despite important efforts.
Healthcare providers will need to contact patients who have been prescribed COUMADIN regarding alternative therapeutic options. We sincerely empathize with patients who will be required to switch to an alternative therapy. We also recognize the burden placed on the healthcare system during this difficult time.
Looking for Answers?
Quick links to helpful resources.
Clinical Trial Information for Researchers
Clinical trials and research are a critical part of bringing new medicines to patients.
Medical Information for Healthcare Providers
Information and resources to assist with caring for patients.